Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

When my daughter had cancer, my other children carried our family with grace, compassion and strength I didn’t know I’d one ...

LaShae D. Rolle discusses how maintaining physical activity during active breast cancer treatment may impact a patients mental and emotional well-being.

TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

The team, which published its findings in JCI Insight, found in preclinical models that JAK inhibitors could possibly stop autoimmune attacks in insulin-producing cells in the pancreas and may be able ...

TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.

An expert helps patients with metastatic breast cancer understand treatment sequencing, biomarker testing and emerging ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells ...

Panelists share that despite initial emotional challenges, multiple myeloma treatment with targeted combination therapies was ...

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic ...

The first patient in the U.S. has been dosed with a novel radioactive medicine to treat advanced breast cancer as part of an international clinical trial.